Good complement goes aHUS bad
OK, so HUS is caused by e.coli toxins and aHUS results from Complement dysregulation. Both are thrombotic microangiopathies. HUS is…
Ravulizumab is not quite eculizumab
Ravulizumab is becoming a treatment of choice for aHUS in countries where access is funded. Though eculizumab will still have a…
Call to action USA aHUS Patients
In Article 462 notice was given of a study to help USA rare disease patients in general. and aHUS patients in…
Withdrawal – need for a consensus
Article No. 457 Yet another article about the outcome of withdrawal of eculizumab treatment has appeared. It is not about a…
aHUS website refreshed
Article No. 456 From today the aHUS alliance Global Action website has a new look. Just over five years since it…
The final aHUS Awareness Day?
Article No. 455 Dr Carla Nester is well known to the hundreds of aHUS families in the USA, and elsewhere, who…
aHUS PREGNANCY COUNSELLING
Article No. 454 aHUS triggered by pregnancy is relatively common and accounts for 16% of female ( 18 to 45 years)…
aHUS Relapse Epilogue: Patient Monitoring
People with atypical HUS need urgent care during periods of disease activity, with treatment when needed for as long as needed.…
aHUS nomenclature project group
Article No. 451 4 August 2021 Following on swiftly from Article No. 450 about the current babble of names and need…
- Go to the previous page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- …
- 48
- Go to the next page